B. Metzler seel. Sohn & Co. AG Trims Stock Holdings in Zoetis Inc. $ZTS

Key Points

• B. Metzler seel. Sohn & Co. AG reduced its Zoetis holdings by 9.7% in the second quarter, selling 13,406 shares and retaining 124,407 shares valued at approximately $8.94 million. Institutional investors collectively own 92.8% of the company.
• Zoetis shares opened at $76.22, near their 52-week low of $71.00 and well below the $155.15 high. The company’s latest quarterly EPS of $1.87 topped estimates, while revenue of $2.47 billion declined slightly year over year.
• Analyst sentiment is mixed, with eight Buy, nine Hold and two Sell ratings; the stock carries a consensus Hold rating and a $107.43 price target. Recent analysts lowered several targets, including JPMorgan’s reduction to $115 and Citigroup’s to $96.

B. Metzler seel. Sohn & Co. AG reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 9.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 124,407 shares of the company's stock after selling 13,406 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Zoetis were worth $8,940,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Prosperity Bancshares Inc bought a new position in Zoetis in the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis during the first quarter worth $28,000. Elyxium Wealth LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at $32,000. Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares during the period. Finally, Wellington Grp LLC grew its holdings in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock worth $32,000 after purchasing an additional 267 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

Shares of ZTS opened at $76.22 on Thursday. The company has a 50 day moving average price of $75.56 and a 200-day moving average price of $94.33. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $155.15. The stock has a market capitalization of $31.50 billion, a PE ratio of 12.56, a PEG ratio of 1.80 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company's quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZTS shares. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research note on Tuesday, August 25th. Zacks Research cut shares of Zoetis from a "hold" rating to a "strong sell" rating in a research report on Monday, August 10th. Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. William Blair reaffirmed a "market perform" rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $107.43.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source